LEU— AI Stock Forecast & Price Targets
Published 7/24/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live LEU price forecast →
Centrus retains genuine strategic scarcity as the sole U.S.-licensed HALEU enricher with a $1.07B DOE contract, $900M Piketon task order, and $1.87B cash — but at $170.78 it trades ~44x forward P/E and ~65x EV/EBITDA while burning ~$58M/quarter in FCF, with a binary Aug 4 earnings print 11 days out. The bounce from $142 to $170 has retraced into prior supply and the 50DMA; risk/reward across the print is unattractive, and I stay HOLD with sizing discipline into the event.
HOLD/no new size into Aug 4 earnings (11 days out). This is a binary print: Q1'26's 41% gross margin needs to be shown as repeatable, not a one-off. Reasonable pre-print range $158-$180. If long already, consider trimming into any push to $178-$182 (prior supply + 50DMA area). Don't chase; if flat, wait for the print. Invalidation for any bullish tactical stance: weekly close below $155. IV crush will punish naked long calls; if expressing a view, define risk. Sentiment at 100% bullish retail into a binary event is a contrarian yellow flag.
1-6 month base case is choppy consolidation in a $150-$200 range as the market digests Q2/Q3 margin durability and Piketon capex cadence. Bull path ($210-$230): two consecutive quarters of 30%+ gross margin AND concrete SMR offtake announcements beyond DOE — this would justify the forward multiple and squeeze the 23% short float. Bear path ($120-$140): Q2 margin reversion toward Q3'25 levels, ATM shelf activation, or Piketon milestone slippage. What would change my mind bullishly: post-print gross margin >30% with positive commentary on 2027 commercial HALEU deliveries. Bearishly: any hint of equity issuance or 2027 timeline slippage.
1-3 year thesis rests entirely on Centrus becoming the durable domestic HALEU monopolist as SMR commercialization (Oklo, X-energy, TerraPower, Kairos) ramps 2027-2030. If Piketon reaches stable commercial output and multi-customer offtakes materialize, revenue could 2-3x and the current multiple compresses through growth rather than de-rating. Terminal fair value in that scenario is meaningfully higher than today. Biggest structural risk: SMR deployment slips into the 2030s (regulatory, financing, or execution), leaving Centrus burning cash against a demand curve that arrives too late. Secondary risks: competing enrichment capacity being funded (Urenco, Orano) that erodes the monopoly, or a policy shift that reopens Russian LEU imports.
Revenue is lumpy and decelerating on a TTM basis ($452M, -4% Y/Y), with the last four quarters swinging from $154.5M → $74.9M → $146.2M → $76.7M — a pattern that makes any single-quarter margin read hazardous. Q1'26 printed a 41% gross margin and 13% net margin, but Q3'25 gross was -5.7% and TTM operating margin is -0.26%; net income is being carried by non-operating items (interest income on the $1.87B cash balance), not core enrichment economics. Balance sheet is a genuine strength: $1.87B cash (~$95/share) vs $1.18B debt, current ratio 5.63, working capital $1.89B — this funds Piketon capex for years without forced dilution. Cash-flow quality, however, is deteriorating: operating cash flow swung from +$52.8M in Q2'25 to -$35.1M in Q1'26, and FCF has been negative in three of four last quarters (-$58M, -$58M, +$5.7M, +$49.2M). ROE of 12.25% and ROIC of 3.11% are underwhelming for the multiple; EPS Q/Q -72% and EPS Y/Y TTM -48.5% show the trend the market is paying up to ignore. Capital allocation is disciplined (no buyback, no dividend, cash preserved for Piketon build-out), which is the right choice given the growth runway but leaves shareholders holding the execution risk.
Across timeframes the picture is a corrective bounce inside a broader downtrend: the weekly chart shows the stock is -63% off the $464 high, the daily shows a clear bottom at $142-$147 followed by a sharp rally back to $170-$174 into the 50DMA (-0.7% from SMA50, +3.8% above SMA20, still -27.7% below SMA200). The 4h chart shows price stalling right at prior consolidation supply around $170-$180. The 1h chart shows momentum flattening near $172 with the forecast band projecting a spike to ~$195 that is inconsistent with the daily/weekly overhead. Critically, the model's own realized directional accuracy on this name runs BELOW naive baseline at multiple horizons (1d 46% vs 62% naive, 1wk 50% vs 50%), and the weekly forecast points to $92 — so I discount both the bullish 1h/4h band and the bearish weekly extrapolation as unreliable and anchor to visible structure. RSI 51.97 is neutral, ATR $11.79 implies ~7% daily range — plenty of room to gap the print. Support: $155-$158 (recent shelf), $142-$147 (major low). Resistance: $180 (round/psychological), $195-$210 (heavy supply from prior distribution). Short float 23.2% is squeeze fuel on a positive surprise but equally accelerant on a miss.
The material signal in the news flow is the July 8 finalization of the $900M fixed-price DOE HALEU task order (part of the broader $1.07B enrichment agreement) — this shifts Piketon from a demonstration pilot to a commercial-scale supply commitment and is the clearest de-risking of the multi-year revenue runway. Analyst posture is mixed but constructive: Truist initiated Buy with a $215 target, Needham maintained Buy but cut target from $314 to $264, and B of A stayed Neutral, cutting target from $240 to $205. The Simply Wall St piece flags the DOE contract as materially altering the investment case, which is fair, but it doesn't change near-term FCF math. Institutional ownership climbed +6.8pp to 78.4% in 45 days, consistent with S&P SmallCap 600 inclusion driving passive/index bid.
- $900M fixed-price DOE task order (finalized July 8, 2026) funds transition from HALEU demonstration to commercial-scale production at Piketon, Ohio
- Sole U.S.-licensed HALEU enricher positions Centrus as the default supplier to the SMR commercialization wave (Oklo, X-energy, TerraPower) targeting 2027-2030 deployments
- $1.87B cash / ~$95/share funds multi-year Piketon capex without near-term dilution, preserving upside if ATM shelf stays dormant
- Q1'26 41% gross margin — if replicated on Aug 4 print, validates the path to sustained operating profitability and forward multiple re-rate
- S&P SmallCap 600 inclusion has driven +6.8pp institutional ownership gain in 45 days to 78.4%, adding a structural passive bid
- 23.2% short float provides asymmetric squeeze fuel on any positive earnings/contract surprise
- Extreme valuation: 44x forward P/E, 65x EV/EBITDA, 7.4x P/S on decelerating TTM sales (-4% Y/Y) leaves no cushion for a Q2 margin miss
- TTM operating margin -0.26% — reported profits are carried by interest income on the cash pile, not core enrichment economics
- FCF burn ~$58M/quarter into Piketon; ATM shelf remains a latent dilution overhang if capex accelerates
- Aug 4 earnings is binary with unreliable post-print direction; sentiment at 100% bullish retail is a contrarian flag
- Revenue lumpiness ($76.7M Q1'26 vs $146.2M Q4'25) makes it hard to underwrite demand durability
- SMR commercialization timeline (2027-2030) slippage would strand the growth runway justifying today's multiple
- Heavy overhead supply in the $195-$250 zone from the prior distribution top argues for multi-quarter basing, not V-recovery
- Weekly forecast model targets $92 — while I discount the specific number given poor realized accuracy, the direction is a reminder of downside asymmetry from these levels
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord